This page shows the latest Sangamo news and features for those working in and with pharma, biotech and healthcare.
Sangamo’s zinc finger protein transcription factor (ZFP-TF) approach involves introducing double-stranded DNA breaks engineered to target specific sequences in a cell. ... Sangamo also has a gene therapy platform, with a first candidate for haemophilia
This includes Sangamo and Pfizer, whose gene therapy achieved a dose-dependent increase in clotting Factor VIII levels across four dosage groups, each including two subjects.
Athough, analysts at Jefferies have previously suggested that with a number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
Updated results presented at ASH 2019. Sangamo has been playing catch-up with BioMarin in the race to develop a gene therapy for haemophilia A, but new data reported at the ... Sangamo is adamant that it is still in contention in the haemophilia A gene
number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a
More from news
Approximately 10 fully matching, plus 20 partially matching documents found.
gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part of a broader R&D alliance.
The success or failure of Bluebird will be closely watched by a slew of cell and gene therapy companies including Sangamo, BioMarin (with exciting potential cures for haemophilia) and UniQure, looking
Editas, and the failure of Sangamo Therapeutics’ rival zinc-finger nucleases (ZFNs) platform. ... Editas, CRISPR, Sangamo, Cellectis/Allogene and their peers to take the slow road to proving that gene- editing can deliver safe and effective
It has gene therapy deals with Spark in haemophilia and with Sangamo in ALS.
320. Sangamo/Biogen Idec . Collaboration and licence. Development of therapies for haemoglobinopathies using zinc finger genome editing.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of business development at Sigma-Aldrich and vice president of business development and alliance management at Sangamo
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...